ARS Pharma director receives 30,000-share option grant
ARS Pharmaceuticals director Rajeev Dadoo received a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ARS Pharmaceuticals director Rajeev Dadoo received a new stock option grant. He was awarded options covering 30,000 shares of common stock at an exercise price of $10.54 per share, expiring on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Dadoo Rajeev
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Key Figures
Option grant size: 30,000 options
Exercise price: $10.54 per share
Underlying shares: 30,000 shares
+2 more
5 metrics
Option grant size
30,000 options
Stock Option (right to buy) granted on June 24, 2026
Exercise price
$10.54 per share
Conversion or exercise price for the stock options
Underlying shares
30,000 shares
Common Stock underlying the option grant
Post-grant derivative holdings
30,000 options
Total derivative securities following the transaction
Option expiration
June 23, 2036
Expiration date of the stock options
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 10.5400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ARS Pharmaceuticals (SPRY) report for Rajeev Dadoo?
ARS Pharmaceuticals reported that director Rajeev Dadoo received a stock option grant for 30,000 shares. The options are a compensation-related award, not an open-market share purchase or sale.
What is the exercise price of Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) stock options?
The stock options have an exercise price of $10.54 per share. This is the price at which he can buy ARS Pharmaceuticals common stock if he chooses to exercise the options in the future.
When do Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) options vest?
The options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting. Vesting must occur before Mr. Dadoo can exercise the options for common shares.
When do Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) stock options expire?
The stock options expire on June 23, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase ARS Pharmaceuticals common stock.
Is Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) Form 4 a buy or sell signal?
The Form 4 reflects a compensation-related stock option grant, not a market trade. It is classified as an acquisition of derivative securities through an award rather than an open-market buy or sell transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
